By Suzanne Elvidge, Contributing Writer
Follow Me On Twitter @suzannewriter
Some takeover deals are hard won, like the plot of a thriller. Tensions rise, contracts are fought out point by point, communications fail, and there are worries about people disappearing. Others are more like romantic movies, where a pair are attracted, get to know each other over a series of dinners in restaurants, talk long into the night, and all ends happily ever after. Fortunately for all involved, the 2018 merger between genome-therapy-focused company Sangamo Therapeutics and TxCell, which focuses on regulatory T-cell (Treg) development for immunological diseases, was more like the latter than the former.